001438400 000__ 05755cam\a2200613\i\4500
001438400 001__ 1438400
001438400 003__ OCoLC
001438400 005__ 20230309004303.0
001438400 006__ m\\\\\o\\d\\\\\\\\
001438400 007__ cr\cn\nnnunnun
001438400 008__ 210724s2021\\\\si\\\\\\o\\\\\000\0\eng\d
001438400 019__ $$a1261049709$$a1266810593
001438400 020__ $$a9789811628702$$q(electronic bk.)
001438400 020__ $$a981162870X$$q(electronic bk.)
001438400 020__ $$z9811628696
001438400 020__ $$z9789811628696
001438400 0247_ $$a10.1007/978-981-16-2870-2$$2doi
001438400 035__ $$aSP(OCoLC)1261366758
001438400 040__ $$aEBLCP$$beng$$erda$$epn$$cEBLCP$$dYDX$$dGW5XE$$dOCLCO$$dYDX$$dEBLCP$$dDCT$$dUKAHL$$dOCLCO$$dOCLCQ$$dSFB$$dOCLCQ
001438400 049__ $$aISEA
001438400 050_4 $$aRC280.P25$$bM36 2021
001438400 08204 $$a616.99/43706$$223
001438400 24500 $$aManagement of pancreatic cancer and cholangiocarcinoma /$$cHiroyuki Isayama, Yousuke Nakai, Takashi Sasaki, editors.
001438400 264_1 $$aSingapore :$$bSpringer,$$c2021.
001438400 300__ $$a1 online resource (318 pages)
001438400 336__ $$atext$$btxt$$2rdacontent
001438400 337__ $$acomputer$$bc$$2rdamedia
001438400 338__ $$aonline resource$$bcr$$2rdacarrier
001438400 347__ $$atext file
001438400 347__ $$bPDF
001438400 500__ $$a6.6 Optimal Regimens for NAT: Chemotherapy or CRT?
001438400 5050_ $$aIntro -- Preface -- Contents -- Part I: Current Topics in Epidemiology and Examinations of Pancreatic Cancer and Cholangiocarcinoma -- 1: Risk Factors for Pancreatic Cancer and Cholangiocarcinoma -- 1.1 Risk Factors for Pancreatic Cancer -- 1.1.1 Introduction -- 1.1.2 Genetic Factors -- 1.1.3 Pancreatic Disorders (Cystic Lesions and Chronic Pancreatitis) -- 1.1.4 Epidemiological Factors -- 1.1.5 Microbiome -- 1.1.6 Discussion -- 1.2 Risk Factors for Cholangiocarcinoma -- 1.2.1 Introduction -- 1.2.2 Microbiome (Infectious Diseases) -- 1.2.3 Genetic Factors
001438400 5058_ $$a1.2.4 Pancreatobiliary and Inflammatory Disorders -- 1.2.5 Epidemiological Factors -- 1.2.6 Discussion -- References -- 2: Detection Strategies and Examination of Early Pancreatic Cancer -- 2.1 Introduction -- 2.2 Clinical Features and Image Findings of Early-Stage PC -- 2.3 Cytological Diagnosis of Early-Stage PC -- 2.4 Pathological Features of Early-Stage PC -- 2.5 Statements and Detection Strategies of Early-Stage PC in Japan -- 2.6 Collaborations Between Specialists and General Practitioners for Early-Stage PC in Japan -- References
001438400 5058_ $$a3: Biomarkers for Pancreatic Cancer and Cholangiocarcinoma -- 3.1 Introduction -- 3.2 Currently Used Biomarkers for PDAC and CCA -- 3.3 Other Protein Markers for PDAC and CCA -- 3.4 Circulating Tumor Cells -- 3.5 Extracellular Vesicles -- 3.6 Biomarker-Based Selection of Targeted Therapies -- 3.7 Conclusion and Future Perspectives -- References -- 4: Recent Advances of Precision Medicine in Pancreatic Cancer and Cholangiocarcinoma -- 4.1 Introduction -- 4.2 Features of Two Reimbursed CGP Tests -- 4.3 Required Tissue Samples -- 4.4 Liquid Biopsy
001438400 5058_ $$a4.5 Eligible Patients for CGP Test and Optimal Timing of Its Application -- 4.6 Clinical Benefit of CGP Tests in Pancreatic Cancer -- 4.7 Clinical Benefit of CGP Tests in Biliary Tract Cancer -- References -- Part II: Anti-cancer Treatments for Pancreatic Cancer -- 5: Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer -- 5.1 Introduction -- 5.2 Metastatic Pancreatic Cancer -- 5.2.1 FOLFIRINOX -- 5.2.2 Gemcitabine Plus Nab-Paclitaxel -- 5.2.3 Selection Between FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel
001438400 5058_ $$a5.2.4 Intraperitoneal Chemotherapy in Patients with Peritoneal Dissemination -- 5.3 Locally Advanced Pancreatic Cancer -- 5.4 The Role of Monotherapy -- 5.5 Second-Line Chemotherapy -- 5.6 Future Perspective -- References -- 6: Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer -- 6.1 Introduction -- 6.2 Preoperative Estimation for Surgical Resectability -- 6.3 Potentially Resectable Tumors -- 6.4 Prospective Studies for NAT and Adjuvant Therapy -- 6.5 Optimal Agent or Regimens for NAT for Potentially Resectable PA
001438400 506__ $$aAccess limited to authorized users.
001438400 520__ $$aThis comprehensive book presents the latest evidence-based data on pancreatobiliary malignancies, including the epidemiology, examination, treatment and endoscopic management. It explores a range of topics, such as risk factors, detection strategies, and novel treatment approaches like precision medicine and immunotherapy. Although there have been rapid improvements in the management of these diseases, the survival period has not yet reached a satisfactory level. This book will help those doctors needing to share the latest information with the patients and their families. It provides a wealth of practical information to help surgeons, endoscopists and oncologists as well as physicians, basic researchers and professionals at medical device and pharmaceutical companies broaden their understanding of the current treatment and management strategies for pancreatobiliary malignancies.
001438400 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed August 9, 2021).
001438400 650_0 $$aPancreas$$xCancer$$xTreatment.
001438400 650_0 $$aBile ducts$$xCancer$$xTreatment.
001438400 650_6 $$aPancréas$$xCancer$$xTraitement.
001438400 655_7 $$aLlibres electrònics.$$2thub
001438400 655_0 $$aElectronic books.
001438400 7001_ $$aIsayama, Hiroyuki.
001438400 7001_ $$aNakai, Yousuke.
001438400 7001_ $$aSasaki, Takashi.
001438400 77608 $$iPrint version:$$aIsayama, Hiroyuki.$$tManagement of Pancreatic Cancer and Cholangiocarcinoma.$$dSingapore : Springer Singapore Pte. Limited, ©2021
001438400 852__ $$bebk
001438400 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-16-2870-2$$zOnline Access$$91397441.1
001438400 909CO $$ooai:library.usi.edu:1438400$$pGLOBAL_SET
001438400 980__ $$aBIB
001438400 980__ $$aEBOOK
001438400 982__ $$aEbook
001438400 983__ $$aOnline
001438400 994__ $$a92$$bISE